MedTrace Logo

TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)

NCT03477903 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2019-09-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the treatment effect of intravenous TAK-954 in improving the average daily protein adequacy received through enteral nutrition in critically-ill participants developing EFI.

Conditions

  • Critical Illness
  • Enteral Nutrition
  • Enteral Feeding Intolerance

Interventions

DRUG

TAK-954

TAK-954 infusion

DRUG

Metoclopramide

Metoclopramide infusion

DRUG

Normal Saline

0.9% sodium chloride for injection

Sponsors & Collaborators

  • Millennium Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Millennium Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-25
Primary Completion
2018-08-29
Completion
2018-08-29
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03477903 on ClinicalTrials.gov